Abstract
In February 2010, aztreonam for inhalation solution (Cayston; Gilead) — an inhalable formulation of the monobactam antibiotic aztreonam and lysine — was approved by the US FDA to improve respiratory symptoms in patients with cystic fibrosis infected with Pseudomonas aeruginosa.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
O'Sullivan, B. P. & Freedman, S. D. Cystic fibrosis. Lancet 373, 1891–1904 (2009).
Geller, D. E. Aerosol antibiotics in cystic fibrosis. Respir. Care 54, 658–670 (2009).
Novartis. Prescribing information — Tobi. Novartis Pharmaceutical Corporation website [online], (2010).
Sykes, R. B. et al. Azthreonam (SQ 26,776), a synthetic monobactam specifically active against aerobic Gram-negative bacteria. Antimicrob. Agents Chemother. 21, 85–92 (1982).
Gibson, R. L. et al. Microbiology, safety, and pharmacokinetics of aztreonam lysinate for inhalation in patients with cystic fibrosis. Pediatr. Pulmonol. 41, 656–665 (2006).
US Food and Drug Administration. FDA labelling information — Cayston. FDA website [online], (2010).
Retsch-Bogart, G. Z. et al. Efficacy and safety of inhaled aztreonam lysine for airway pseudomonas in cystic fibrosis. Chest 135, 1223–1232 (2009).
Jensen, T. et al. Colistin inhalation therapy in cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infection. J. Antimicrob. Chemother. 19, 831–838 (1987).
McCoy, K. S. et al. Inhaled aztreonam lysine for chronic airway Pseudomonas aeruginosa in cystic fibrosis. Am. J. Respir. Crit. Care Med. 178, 921–928 (2008).
Flume, P. A. et al. Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health. Am. J. Respir. Crit. Care Med. 176, 957–969 (2007).
Smith, B. A. & Wood, B. L. Psychological factors affecting disease activity in children and adolescents with cystic fibrosis: medical adherence as a mediator. Curr. Opin. Pediatr. 19, 553–558 (2007).
Ashlock, M. A. et al. A pipeline of therapies for cystic fibrosis. Semin. Respir. Crit. Care Med. 30, 611–626 (2009).
IMS MIDAS (IMS Health, 2009).
European Medicines Agency. Final assessment report for Cayston. International nonproprietary name: aztreonam. Procedure No. EMEA/H/C/000996. EMA website [online], (2009).
Wei, T., Deepak, S. & Nguyen, T. Equity research report. (Jefferies & Company Inc.; February 2010).
Author information
Authors and Affiliations
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
O'Sullivan, B., Yasothan, U. & Kirkpatrick, P. Inhaled aztreonam. Nat Rev Drug Discov 9, 357–358 (2010). https://doi.org/10.1038/nrd3170
Issue Date:
DOI: https://doi.org/10.1038/nrd3170
